A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies.
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
The combination of brain radiotherapy and chemoimmunotherapy “resulted in promising intracranial and systemic anti-tumor activity, with a manageable safety profile,” researchers wrote.
Daniel Rubin, PharmD, BCOP, discussed a study showing how a clinical decision support tool can improve the documentation of biomarker results in cancer care.
Media ReleaseMarking Immutep’s transition to a Phase III biotech, the Company’s pivotal TACTI-004 trial in first-line non-small cell lung cancer ...
The findings suggest that reconsideration of current clinical guidelines, which support MRI only for symptomatic brain ...
We must come together to combat air pollution and move to clean energy to prevent more needless deaths from lung cancer.
The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.
Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...
OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...
Discussions also delved into the complexities of value-based oncology care, the growing role of real-world data, and strategies to improve access to care in hematology. Across all sessions, a common ...
Lung metastases are a devastating reality for over half of cancer patients whose tumors spread beyond their initial sites.